GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (OTCPK:LZAGY) » Definitions » Price-to-Owner-Earnings

Lonza Group (Lonza Group) Price-to-Owner-Earnings : 65.67 (As of Apr. 27, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Lonza Group Price-to-Owner-Earnings?

As of today (2024-04-27), Lonza Group's share price is $57.79. Lonza Group's Owner Earnings per Share (TTM) ended in Dec. 2023 was $0.88. It's Price-to-Owner-Earnings for today is 65.67.


The historical rank and industry rank for Lonza Group's Price-to-Owner-Earnings or its related term are showing as below:

LZAGY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.57   Med: 31.55   Max: 78.41
Current: 65.39

During the past 13 years, the highest Price-to-Owner-Earnings of Lonza Group was 78.41. The lowest was 11.57. And the median was 31.55.


LZAGY's Price-to-Owner-Earnings is ranked worse than
85.29% of 68 companies
in the Medical Diagnostics & Research industry
Industry Median: 25.395 vs LZAGY: 65.39

As of today (2024-04-27), Lonza Group's share price is $57.79. Lonza Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.00. Therefore, Lonza Group's PE Ratio for today is 57.73.

As of today (2024-04-27), Lonza Group's share price is $57.79. Lonza Group's EPS without NRI for the trailing twelve months (TTM) ended in was $1.41. Therefore, Lonza Group's PE Ratio without NRI for today is 41.13.

During the past 13 years, Lonza Group's highest PE Ratio without NRI was 79.53. The lowest was 13.60. And the median was 27.56.


Lonza Group Price-to-Owner-Earnings Historical Data

The historical data trend for Lonza Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group Price-to-Owner-Earnings Chart

Lonza Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.85 56.71 19.83 37.79 43.84

Lonza Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.83 - 37.79 - 43.84

Competitive Comparison of Lonza Group's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, Lonza Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lonza Group's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Lonza Group's Price-to-Owner-Earnings falls into.



Lonza Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Lonza Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=57.79/0.88
=65.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lonza Group  (OTCPK:LZAGY) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Lonza Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Lonza Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Lonza Group (Lonza Group) Business Description

Address
Muenchensteinerstrasse 38, Basel, CHE, CH-4002
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.